Clone:
REA110
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, ICC, MC
Alternative names:
KLRC1, CD159a, NKG2, NKG2A

Extended validation for CD159a (NKG2A) Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA110
131411-
Z199++
REAL283++
Cells were incubated with an excess of purified unconjugated CD159a (NKG2A) (REA110) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD159a (NKG2A). Human peripheral blood mononuclear cells (PBMCs) were stained with CD159a (NKG2A) antibodies and with a suitable counterstaining. As a control, CD159a (NKG2A) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD159a (NKG2A). Human peripheral blood mononuclear cells (PBMCs) were stained with CD159a (NKG2A) antibodies and with a suitable counterstaining. As a control, CD159a (NKG2A) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD159a (NKG2A). Human peripheral blood mononuclear cells (PBMCs) were stained with CD159a (NKG2A) antibodies and with a suitable counterstaining. As a control, CD159a (NKG2A) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD159a (NKG2A). Human peripheral blood mononuclear cells (PBMCs) were stained with CD159a (NKG2A) antibodies and with a suitable counterstaining. As a control, CD159a (NKG2A) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD159a (NKG2A). Human peripheral blood mononuclear cells (PBMCs) were stained with CD159a (NKG2A) antibodies and with a suitable counterstaining. As a control, CD159a (NKG2A) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD159a (NKG2A) (REA110). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD159a (NKG2A) (REA110). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD159a (NKG2A) (REA110). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD159a (NKG2A) Antibody, anti-human, REAfinity™

Overview

Clone REA110 recognizes CD159a, an inhibitory natural killer (NK) cell receptor. CD159a forms heterodimer with CD94 and contains a C-type lectin ectodomain. Inhibitory signal is transmitted by the heterodimer via immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and upon ligand engagement, ITIMs are phosphorylated and transmit signal through docking of various tyrosine phosphatases. CD159a/CD94 binds non-classical MHC class I protein, HLA-E. Expression of CD159a is found mainly on NK cells and on subsets of CD8
+
cells.
Additional information: Clone REA110 displays negligible binding to Fc receptors.

Alternative names

KLRC1, CD159a, NKG2, NKG2A

Detailed product information

Technical specifications

CloneREA110
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman, non-human primate
Cross-reactivity
chimpanzee (
Pan troglodytes
)
,
olive baboon (
Papio anubis
)
,
rhesus monkey (
Macaca mulatta
)
,
cynomolgus monkey (
Macaca fascicularis
)
AntigenCD159a (NKG2A)
Alternative names of antigenKLRC1, CD159a, NKG2, NKG2A
Molecular mass of antigen [kDa]26
Distribution of antigenT cells, NK cells
Entrez Gene ID3821
RRIDAB_2733623, AB_2726450, AB_2726173, AB_2726448, AB_2726171, AB_2726447, AB_2726170, AB_2726449, AB_2726172, AB_2783969, AB_2783968, AB_2801749, AB_2801742, AB_2801908, AB_2733622

Resources for CD159a (NKG2A) Antibody, anti-human, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD159a (NKG2A) Antibody, anti-human, REAfinity™

Publications

  1. Rueda, C. et al. (2016)
    Lipopolysaccharide-induced chorioamnionitis promotes IL-1-dependent inflammatory FOXP3
    +
    CD4
    +
    T cells in the fetal rhesus macaque.
    J. Immunol. 196(9): 3706-3715
  2. Boyington, J. C. et al. (1999) Structure of CD94 reveals a novel C-type lectin fold: implications for the NK cell-associated CD94/NKG2 receptors. Immunity 10(1): 75-82
  3. Sullivan, L. C. et al. (2007) The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition. Immunity 27(6): 900-911
  4. Reeves R. K. et al. (2015) Antigen-specific NK cell memory in rhesus macaques. Nat. Immunol. 16: 927-932
  5. Veluchamy, J. P. et al. (2017) High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status. Cancer Immunol. Immunother. 66: 51-61
  6. Wolpert, F. et al. (2015) Interferon-β modulates the innate immune response against glioblastoma initiating cells. PLoS One 10(10): e0139603
  7. Borrego, F. et al. (2006) The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance. Immunol. Res. 35(3): 263-278
  8. Croci, S. et al. (2018) Higher frequencies of lymphocytes expressing the natural killer group 2D receptor in patients with Behçet disease. Front Immunol 9: 2157
  9. Jacomet, F. et al. (2017)
    The hypothesis of the human iNKT/innate CD8
    +
    T-cell axis applied to cancer: evidence for a deficiency in chronic myeloid leukemia.
    Front Immunol 7: 688
  10. Mahaweni, N. et al. (2018)
    NKG2A expression is not
    per se
    detrimental for the anti-multiple myeloma activity of activated natural killer cells in an
    in vitro
    system mimicking the tumor microenvironment.
    Front Immunol 9: 1415
  11. Rechtien, A. et al. (2017) Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV. Cell Rep 20(9): 2251-2261

Related products for
CD159a (NKG2A) Antibody, anti-human, REAfinity™

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?